OCUP Insider Trading Activity and SEC Form 4 Filings
OCUP insider trading summary
No open-market insider purchases or sales of Ocuphire Pharma, Inc. (OCUP) have been reported on SEC Form 4 in the past 12 months.
Latest OCUP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 22, 2024 | Ashwath Jayagopal | Chief Scientific & Dev. Ofc. | Buy | $6K (3,500 @ $1.76) |
| May 17, 2024 | George Magrath | Chief Executive Officer | Buy | $9K (5,000 @ $1.75) |
| Mar 21, 2024 | Nirav S. Jhaveri | Chief Financial Officer | Buy | $21K (10,000 @ $2.10) |
| Mar 21, 2024 | Joseph K Schachle | Chief Operating Officer | Buy | $4K (2,000 @ $2.05) |
| Mar 18, 2024 | George Magrath | Chief Executive Officer | Buy | $49K (25,000 @ $1.96) |
| May 20, 2022 | Mina Sooch | President and CEO | Buy | $25K (12,500 @ $2.02) |
| May 20, 2022 | James S J Manuso | Insider | Buy | $10K (5,000 @ $1.99) |
| May 19, 2022 | Mina Sooch | President and CEO | Buy | $26K (12,500 @ $2.07) |
| Dec 13, 2021 | Jay Pepose | Insider | Buy | $30K (8,250 @ $3.65) |
| Nov 18, 2021 | James S J Manuso | Insider | Buy | $7K (2,000 @ $3.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.